EUCTR2006-006633-41-DE进行中（未招募）不适用
Monocenter, open-label, randomized study to determine the ovulation inhibitory effect of the combined oral contraceptives SH T04769G (0.015 mg Ethinylestradiol and 1.5 mg Dienogest in a modified release medicinal product) and SH D00659AF (0.03 mg Ethinylestradiol and 2.0 mg Dienogest), applied for two treatment cycles to 60 healthy female volunteers - Valette low ovulation inhibition
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- healthy female volunteers aged between 18 and 35 years (inclusive), smokers not older than 30 years (inclusive) at inclusion
- •- follicular diameter >= 15 mm before Visit 6 / admission to treatment or observed ovulation during pre-treatment cycle, absence of premature follicular ripening
- •- non-suspicious cervical smear taken at Screening
- •- signed and dated informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Pregnancy, lactation (less than 3 cycles following delivery, abortion, or lactation before start of pre-treatment cycle)
- •- Known hypersensitivity to any ingredients of the study medication, e.g. patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
- •- Any known diseases or conditions that compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication
- •- Any known severe systemic disease that might interfere with the conduct of the study or the interpretation of the results
- •- Uncontrolled thyroid disorders
- •- Clinically significant depression (current or in the last year)
- •- Abnormal, clinically significant findings which, according to the assessment of the investigator, may worsen under hormonal treatment (e.g., pemphigoid gestationis during a previous pregnancy; middle-ear deafness (otosclerosis); sydenham chorea, porphyria, systemic lupus erythematodes, hemolytic uremic syndrome)
- •- Laboratory values outside inclusion range at Screening
- •- Participation in another clinical study or administration of an investigational drug within 1 month prior to study entry (Visit 1)
- •- Operations scheduled in the study period
- •- Liver diseases: acute and chronic progressive liver diseases, e.g., disturbances of the bilirubin excretion of the bile (Dubin-Johnson and Rotor syndromes) , disturbances of the bile secretion, disturbances in the bile flow, idiopathic icterus or pruritus during a previous pregnancy or estrogen-progestogen treatment.
- •Presence or history of liver tumors (benign or malignant)
- •Existing or previous hepatic disease as long as liver function values have not returned to normal. There should be an interval of at least 3 months between the start of study medication intake and the return of liver function values to normal.
- •- Pancreatitis or a history thereof if associated with severe hypertriglyceridemia
- •- Vascular diseases and coagulation disorders:
- •Existing or previous venous thromboembolic diseases (deep vein thrombosis, pulmonary embolism), existing or previous arterial thromboembolic diseases (myocardial infarction, stroke), presence or history of prodromi of a thrombosis (e.g., transient ischemic attack, angina pectoris), existing or previous cerebrovascular accident, as well as any condition that could increase the risk of any of the above, e.g., hereditary or acquired predisposition for venous or arterial thrombosis, such as APC-resistance, Antithrombin III (AT-III) deficiency, Protein-C and/or Protein-S deficiency, hyperhomocysteinemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant), any venous thromboembolic event that occurred in a close relative at a younger age (= 50 years), specific heart diseases (e.g., valvular heart disease, atrial fibrillation) cardiac dysfunction (NYHA I-IV), pronounced varicosis veins, mild varicosis veins or previous phlebitis in combination with other risk factors
- •- Uncontrolled arterial hypertension (confirmed systolic blood pressure > 140 mmHg or confirmed diastolic blood pressure > 90 mmHg)
- •- Known diabetes mellitus
- •- Sickle-cell anemia
- •- Known severe disturbances of lipid metabolism
- •- Known or suspected malignant or premalignant steroid-hormone dependent diseases (e.g., endometrial cancer, breast cancer), also a history thereof. Volunteers with other malignancies / premalignanci
研究者
相似试验
进行中（未招募）
不适用
A mono center, open-label, randomized study examining the effects of intra-dermal vs. subcutaneous application of regular human insulin or rapid-acting insulin analogue on postprandial glycemic excursions in patients with type 1 diabetesThe study will be performed in Type 1 DiabeticsEUCTR2007-003924-39-DEBecton, Dickinson and Company30
招募中
不适用
To study whether local application of Ultraviolet C radiation along with Methylene Blue eyedrops is beneficial and safe in compared to antimicrobial eye drops in treatment of corneal ulcersCTRI/2021/08/035870Divyajyoti Trust
尚未招募
不适用
This is an open label single centre study to evaluate the safety and efficacy of anti acne formulation in patients with facial acne.CTRI/2019/10/021562Sami Labs Limited
已完成
2 期
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cyclescontraceptionFertility controlNL-OMON34076Bayer110
进行中（未招募）
不适用
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetic study of 3 transdermal EE and GSD formulationsPrevention of PregnancyMedDRA version: 12.1Level: LLTClassification code 10060346Term: Transdermal contraceptionEUCTR2010-021255-81-NLBayer HealthCare AG174